Angelini said to be explore acquisition of Catalyst Pharma (CPRX)
Context
Angelini exploring the acquisition of Catalyst Pharma indicates potential strategic consolidation in the biotech sector. If the deal is accretive and seen as a positive move for Angelini, it could spur similar M&A activity among peers or impact investor sentiment in the sector. Keep an eye on how market participants react, especially regarding pricing multiples and the regulatory landscape.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#CATALYST PHARMACEUTICAL PARTNERS#CPRX.US#EU SESSION#US SESSION#US EQUITIES